Nemolizumab-Ilto 30 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 30 mg/mL

Reference Brands: Nemluvio (USA)

Category: Derma Drugs

Nemolizumab-ilto 30 mg injection, an interleukin-31 receptor antibody given by subcutaneous pen for prurigo nodularis and atopic dermatitis, for hospital pharmacies, specialty distributors and importers.

Product Description:

Nemolizumab is a humanised monoclonal antibody that blocks the interleukin-31 receptor alpha. Interleukin-31 is a key itch signal from immune cells to skin nerves and also takes part in inflammation and barrier changes. Blocking its receptor dampens this signalling, which is central in prurigo nodularis and atopic dermatitis. The suffix -ilto is the code the US FDA adds to biologic names. This page lists the 30 mg subcutaneous presentation, supplied in the US as a dual-chamber prefilled pen of powder and diluent.

In the US it is approved for adults with prurigo nodularis and for patients aged 12 and over with moderate to severe atopic dermatitis, used with topical corticosteroids or calcineurin inhibitors when topical prescription therapy is not enough. Dosing starts with a loading dose, then injections every four weeks; in atopic dermatitis the interval may widen for good responders. Patients or carers can inject after training. Hypersensitivity is the main listed precaution, and live vaccines are avoided during therapy.

Sourcing notes. Nemolizumab is a prescription-only biologic registered in a limited number of markets so far, so confirm local approval or a named-patient route before quoting. Pens need a 2-8 °C cold chain, kept in the carton away from light and never frozen; ship with temperature loggers. Check the listed 30 mg/mL strength against the registered presentation, since labels state the dose per pen. Ask for the batch CoA and release certificate, biologic GMP certificate, CoPP and risk management plan summary. State pen count and minimum shelf life.